Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanassios Dimopoulos

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Cancer Medicine|September 22, 2018
Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapyMarinos Tsiatas, Konstantine T Kalogeras, Kyriaki Manousou, et al.
Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.
BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.
Hematological Oncology|May 22, 2012
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without RituximabSotirios G Papageorgiou, Panayiotis Diamantopoulos, Georgia Levidou, et al.
Plos One|August 1, 2018
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trialAnna Goussia, Nafsika Simou, Flora Zagouri, et al.
The Lancet. Oncology|April 4, 2017
Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupMichele Cavo, Evangelos Terpos, Cristina Nanni, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Cancer Medicine|September 22, 2018
Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapyMarinos Tsiatas, Konstantine T Kalogeras, Kyriaki Manousou, et al.
Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.
BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.
Hematological Oncology|May 22, 2012
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without RituximabSotirios G Papageorgiou, Panayiotis Diamantopoulos, Georgia Levidou, et al.
Plos One|August 1, 2018
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trialAnna Goussia, Nafsika Simou, Flora Zagouri, et al.
The Lancet. Oncology|April 4, 2017
Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupMichele Cavo, Evangelos Terpos, Cristina Nanni, et al.
Annals of Hematology|February 1, 2021
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategiesTheodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, et al.
Pageof 6